Literature DB >> 17093101

Dynamics of the immune response against extracellular products of group A streptococci during infection.

Linda Maripuu1, Anna Eriksson, Björn Eriksson, Karlis Pauksen, Stig Holm, Mari Norgren.   

Abstract

The immune response against the infecting group A streptococcus (GAS) extracellular products (EP) was determined in acute- and convalescent-phase sera from 75 patients with different clinical manifestations of GAS infection. All EP elicited a high proliferative response in human peripheral blood mononuclear cells. In patients with bacteremia, low neutralization in acute-phase sera was associated with development of streptococcal toxic shock syndrome. Lack of neutralization in acute-phase sera was more common in patients infected with the T1emm1 serotype. The majority of patients did not develop the ability to neutralize the mitogenic activity of their infecting isolate despite a significant increase in enzyme-linked immunosorbent assay titer in early convalescent-phase sera. In patients with the ability to neutralize GAS EP, the immune response remained high over at least 3 years. In contrast, the neutralization capacity conferred by intravenous immunoglobulin and/or plasma treatment disappeared within 3 months.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17093101      PMCID: PMC1797706          DOI: 10.1128/CVI.00271-06

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  36 in total

Review 1.  Toxic shock syndrome and bacterial superantigens: an update.

Authors:  J K McCormick; J M Yarwood; P M Schlievert
Journal:  Annu Rev Microbiol       Date:  2001       Impact factor: 15.500

2.  Host variation in cytokine responses to superantigens determine the severity of invasive group A streptococcal infection.

Authors:  A Norrby-Teglund; S Chatellier; D E Low; A McGeer; K Green; M Kotb
Journal:  Eur J Immunol       Date:  2000-11       Impact factor: 5.532

Review 3.  Molecular basis of group A streptococcal virulence.

Authors:  A L Bisno; M O Brito; C M Collins
Journal:  Lancet Infect Dis       Date:  2003-04       Impact factor: 25.071

4.  Invasive group A streptococcal infections: T1M1 isolates expressing pyrogenic exotoxins A and B in combination with selective lack of toxin-neutralizing antibodies are associated with increased risk of streptococcal toxic shock syndrome.

Authors:  B K Eriksson; J Andersson; S E Holm; M Norgren
Journal:  J Infect Dis       Date:  1999-08       Impact factor: 5.226

5.  SIC, a secreted protein of Streptococcus pyogenes that inactivates antibacterial peptides.

Authors:  Inga-Maria Frick; Per Akesson; Magnus Rasmussen; Artur Schmidtchen; Lars Björck
Journal:  J Biol Chem       Date:  2003-03-05       Impact factor: 5.157

6.  Insight into the molecular basis of pathogen abundance: group A Streptococcus inhibitor of complement inhibits bacterial adherence and internalization into human cells.

Authors:  Nancy P Hoe; Robin M Ireland; Frank R DeLeo; Brian B Gowen; David W Dorward; Jovanka M Voyich; Mengyao Liu; Eugene H Burns; Derek M Culnan; Anthony Bretscher; James M Musser
Journal:  Proc Natl Acad Sci U S A       Date:  2002-05-28       Impact factor: 11.205

7.  An immunogenetic and molecular basis for differences in outcomes of invasive group A streptococcal infections.

Authors:  Malak Kotb; Anna Norrby-Teglund; Allison McGeer; Hesham El-Sherbini; M Tevik Dorak; Ayesha Khurshid; Karen Green; Jeanie Peeples; Judy Wade; Glenys Thomson; Benjamin Schwartz; Donald E Low
Journal:  Nat Med       Date:  2002-11-18       Impact factor: 53.440

8.  Evidence for superantigen involvement in severe group a streptococcal tissue infections.

Authors:  A Norrby-Teglund; P Thulin; B S Gan; M Kotb; A McGeer; J Andersson; D E Low
Journal:  J Infect Dis       Date:  2001-08-15       Impact factor: 5.226

9.  Differential presentation of group A streptococcal superantigens by HLA class II DQ and DR alleles.

Authors:  Anna Norrby-Teglund; Gerald T Nepom; Malak Kotb
Journal:  Eur J Immunol       Date:  2002-09       Impact factor: 5.532

10.  Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: a European randomized, double-blind, placebo-controlled trial.

Authors:  Jessica Darenberg; Nahla Ihendyane; Jan Sjölin; Ewa Aufwerber; Sven Haidl; Per Follin; Jan Andersson; Anna Norrby-Teglund
Journal:  Clin Infect Dis       Date:  2003-07-17       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.